Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Immunological monitoring of patients receiving immunotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.18
Views: 279

Prof Jaques van Dongen - Leiden University, Netherlands

Prof Jaques van Dongen talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the immunological monitoring of patients.

Prof van Dongen discusses that of the hot topics is the detection of minimal residual disease (MRD) and how this has become the standard technology.

He also explains that it is key to investigate how leukaemic cells decrease during treatment and how normal B-cells regenerate as this can identify a presence of leukaemic cells that otherwise could not be seen.


ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation